# US 2014/0212417 A1 · Prolonged inhibition of interleukin-6 mediated signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0212417 A1
- Document ID: US20140212417A1
- Status: Published application
- Kind: A1
- Application number: 14/345,702
- Filed: 2012-09-24
- Published: 2014-07-31
- Earliest claimed: 2011-09-23
- Assignees: Ablynx N.V.
- Applicants: Ablynx N.V.
- Inventors: Josefin-Beate Holz; Stefaan Rossenu; Steven De Bruyn; Maria Laura Sargentini-Maier; Özkan Yalkinoglu
- Web page: https://patentgrep.com/patent/US20140212417A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 14/5412: {IL-6}
- C07K 14/7155: {for interleukins [IL]}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.

## Claims

### Claim 1

A method for inhibiting IL-6 mediated signaling in a subject comprising administering to the subject a polypeptide that specifically binds IL-6R, wherein the amount of the polypeptide administered is effective:
to increase total sIL-6R levels in serum to at least 400 ng/ml and to maintain total sIL-6R levels in serum at least 400 ng/ml;
to increase total IL-6 levels in serum to at least 40 pg/ml and to maintain total IL-6 levels in serum at least 40 pg/ml;
to reduce CRP levels in serum below 10 mg/l and to maintain CRP levels in serum below 10 mg/l;
to reduce CRP levels in serum by 50% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain CRP levels in serum at 50% or more reduction compared to baseline levels;
to reduce ESR levels in serum by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain ESR levels in serum at 30% or more reduction compared to baseline levels;
to reduce fibrinogen levels in serum by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain fibrinogen levels in serum at 30% or more reduction compared to baseline levels; and/or
to reduce serum amyloid A levels by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain serum amyloid A levels at 30% or more reduction compared to baseline levels;
for at least 4 weeks after administration.

### Claim 2

A polypeptide that specifically binds IL-6R for treatment of diseases and/or disorders associated with IL-6 mediated signaling, wherein the amount of the polypeptide administered is effective
to increase total sIL-6R levels in serum to at least 400 ng/ml and to maintain total sIL-6R levels in serum at least 400 ng/ml;
to increase total IL-6 levels in serum to at least 40 pg/ml and to maintain total IL-6 levels in serum at least 40 pg/ml;
to reduce CRP levels in serum below 10 mg/l and to maintain CRP levels in serum below 10 mg/l;
to reduce CRP levels in serum by 50% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain CRP levels in serum at 50% or more reduction compared to baseline levels;
to reduce ESR levels in serum by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain ESR levels in serum at 30% or more reduction compared to baseline levels;
to reduce fibrinogen levels in serum by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain fibrinogen levels in serum at 30% or more reduction compared to baseline levels; and/or
to reduce serum amyloid A levels by 30% or more compared to baseline (i.e. pre-treatment or normal) levels and to maintain serum amyloid A levels at 30% reduction or more compared to baseline levels;
for at least 4 weeks after administration.

### Claim 3 (depends on 1, 2)

The method of claim 1 or the polypeptide of claim 2, wherein the polypeptide comprises one or more immunoglobulin single variable domain that specifically binds IL-6R and that essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
a) CDR1 is chosen from the group consisting of: SEQ ID NO's: 17-19;
b) CDR2 is chosen from the group consisting of: SEQ ID NO's: 21-28; and
c) CDR3 is chosen from the group consisting of: SEQ ID NO's: 30-32.

### Claim 4 (depends on 3)

The method or the polypeptide of claim 3, in which:
a) CDR1 is SEQ ID NO: 17;
b) CDR2 is SEQ ID NO: 21; and
c) CDR3 is SEQ ID NO: 30.

### Claim 5 (depends on 3)

The method or the polypeptide of claim 3, wherein the one or more immunoglobulin single variable domain is selected from any of SEQ ID NOs: 1-10.

### Claim 6 (depends on 5)

The method or the polypeptide of claim 5, wherein the one or more immunoglobulin single variable domain is selected SEQ NOs: 1.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method or the polypeptide of any of claims 1 to 6, wherein the polypeptide comprises at least one half-life extension moiety.

### Claim 8 (depends on 7)

The method or the polypeptide of claim 7, wherein the at least one half-life extension moiety specifically binds a serum protein.

### Claim 9 (depends on 8)

The method or the polypeptide of claim 8, wherein the serum protein is selected from serum albumin, and in particular human serum albumin, thyroxine-binding protein, (human) transferrin, fibrinogen, an immunoglobulin, such as IgG, IgE or IgM, or one of the serum proteins listed in WO 04/003019.

### Claim 10 (depends on 7, 8, 9)

The method or the polypeptide of any of claims 7 to 9, wherein the at least one half-life extension moiety comprises or consists of an immunoglobulin single variable domain.

### Claim 11 (depends on 10)

The method or the polypeptide of claim 10, wherein the immunoglobulin single variable domain is selected from VHH domains, humanized VHH domains, camelized VH domains, domain antibodies, single domain antibodies and/or “dAb”s.

### Claim 12 (depends on 11)

The method or the polypeptide of claim 11, wherein the immunoglobulin single variable domain is selected from SEQ ID NO's: 37-39.

### Claim 13 (depends on 2)

The method or the polypeptide of claim 2, wherein the polypeptide is selected from any of SEQ ID NOs: 34-36.

### Claim 14 (depends on 2)

The method or the polypeptide of claim 2, wherein the polypeptide is SEQ ID NO: 34.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method or the polypeptide of any of claims 1 to 14, wherein the subject is suffering from a disease and/or disorder selected from sepsis, cancer (such as multiple myeloma disease (MM), renal cell carcinoma (RCC), plasma cell leukaemia, lymphoma, B-lymphoproliferative disorder (BLPD) and prostate cancer), bone resorption (osteoporosis), cachexia, psoriasis, mesangial proliferative glomerulonephritis, Kaposi's sarcoma, AIDS-related lymphoma, an inflammatory disease and/or disorder (such as rheumatoid arthritis, systemic onset juvenile idiopathic arthritis, hypergammaglobulinemia, Crohn's disease, ulcerative colitis, systemic lupus erythematosus (SLE), multiple sclerosis, Castleman's disease, IgM gammopathy, cardiac myxoma, asthma (in particular allergic asthma) and autoimmune insulin-dependent diabetes mellitus).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method or the polypeptide of any of claims 1 to 15, wherein the subject is suffering from rheumatoid arthritis.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method or the polypeptide of any of claims 1 to 16, wherein the polypeptide is administered in an amount from about 0.3 mg/kg to about 10 mg/kg.

### Claim 18 (depends on 17)

The method or the polypeptide of claim 17, wherein the polypeptide is administered in an amount of about 0.3 mg/ml.

### Claim 19 (depends on 17)

The method or the polypeptide of claim 17, wherein the polypeptide is administered in an amount from about 1 mg/kg to about 10 mg/kg.

### Claim 20 (depends on 19)

The method or the polypeptide of claim 19, wherein the polypeptide is administered in an amount of about 1 mg/kg.

### Claim 21 (depends on 19)

The method or the polypeptide of claim 19, wherein the polypeptide is administered in an amount from about 3 mg/kg to about 6 mg/kg.

### Claim 22 (depends on 21)

The method or the polypeptide of claim 21, wherein the polypeptide is administered in an amount of about 3 mg/kg.

### Claim 23 (depends on 21)

The method or the polypeptide of claim 21, wherein the polypeptide is administered in an amount of about 6 mg/kg.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method or the polypeptide of any of claims 1 to 23, wherein the polypeptide is administered as a single dose.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method or the polypeptide of any of claims 1 to 24, wherein total sIL-6R levels in serum are increased to at least 400 ng/ml within two weeks after administration.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method or the polypeptide of any of claims 1 to 25, wherein total sIL-6R levels in serum are increased to and maintained at least 400 ng/ml for at least 4 weeks after administration.

### Claim 27 (depends on 26)

The method or the polypeptide of claim 26, wherein total sIL-6R levels in serum are maintained at least 400 ng/ml for at least 5 weeks after administration.

### Claim 28 (depends on 27)

The method or the polypeptide of claim 27, wherein total sIL-6R levels in serum are maintained at least 400 ng/ml for at least 6 weeks after administration.

### Claim 29 (depends on 28)

The method or the polypeptide of claim 28, wherein total sIL-6R levels in serum are maintained at least 400 ng/ml for at least 7 weeks after administration.

### Claim 30 (depends on 29)

The method or the polypeptide of claim 29, wherein total sIL-6R levels in serum are maintained at least 400 ng/ml for at least 8 weeks after administration.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method or the polypeptide of any of claims 1 to 30, wherein total sIL-6R levels in serum are increased to and maintained at least 500 ng/ml for at least 4 weeks after administration.

### Claim 32 (depends on 31)

The method or the polypeptide of claim 31, wherein total sIL-6R levels in serum are maintained at least 500 ng/ml for at least 5 weeks after administration.

### Claim 33 (depends on 32)

The method or the polypeptide of claim 32, wherein total sIL-6R levels in serum are maintained at least 500 ng/ml for at least 6 weeks after administration.

### Claim 34 (depends on 33)

The method or the polypeptide of claim 33, wherein total sIL-6R levels in serum are maintained at least 500 ng/ml for at least 7 weeks after administration.

### Claim 35 (depends on 34)

The method or the polypeptide of claim 34, wherein total sIL-6R levels in serum are maintained at least 500 ng/ml for at least 8 weeks after administration.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method or the polypeptide of any of claims 1 to 35, wherein total sIL-6R levels in serum are increased to and maintained at least 600 ng/ml for at least 4 weeks after administration.

### Claim 37 (depends on 36)

The method or the polypeptide of claim 36, wherein total sIL-6R levels in serum are maintained at least 600 ng/ml for at least 5 weeks after administration.

### Claim 38 (depends on 37)

The method or the polypeptide of claim 37, wherein total sIL-6R levels in serum are maintained at least 600 ng/ml for at least 6 weeks after administration.

### Claim 39 (depends on 38)

The method or the polypeptide of claim 38, wherein total sIL-6R levels in serum are maintained at least 600 ng/ml for at least 7 weeks after administration.

### Claim 40 (depends on 39)

The method or the polypeptide of claim 39, wherein total sIL-6R levels in serum are maintained at least 600 ng/ml for at least 8 weeks after administration.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method or the polypeptide of any of claims 1 to 40, wherein total IL-6 levels in serum are increased to at least 40 pg/ml within two weeks after administration.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method or the polypeptide of any of claims 1 to 41, wherein total IL-6 levels in serum are increased to and maintained at least 40 pg/ml for at least 4 weeks after administration.

### Claim 43 (depends on 42)

The method or the polypeptide of claim 42, wherein total IL-6 levels in serum are maintained at at least 40 pg/ml for at least 5 weeks after administration.

### Claim 44 (depends on 43)

The method or the polypeptide of claim 43, wherein total IL-6 levels in serum are maintained at at least 40 pg/ml for at least 6 weeks after administration.

### Claim 45 (depends on 44)

The method or the polypeptide of claim 44, wherein total IL-6 levels in serum are maintained at at least 40 pg/ml for at least 7 weeks after administration.

### Claim 46 (depends on 45)

The method or the polypeptide of claim 45, wherein total IL-6 levels in serum are maintained at at least 40 pg/ml for at least 8 weeks after administration.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method or the polypeptide of any of claims 1 to 46, wherein total IL-6 levels in serum are increased to and maintained at least 50 pg/ml for at least 4 weeks after administration.

### Claim 48 (depends on 47)

The method or the polypeptide of claim 47, wherein total IL-6 levels in serum are maintained at at least 50 pg/ml for at least 5 weeks after administration.

### Claim 49 (depends on 48)

The method or the polypeptide of claim 48, wherein total IL-6 levels in serum are maintained at at least 50 pg/ml for at least 6 weeks after administration.

### Claim 50 (depends on 49)

The method or the polypeptide of claim 49, wherein total IL-6 levels in serum are maintained at at least 50 pg/ml for at least 7 weeks after administration.

### Claim 51 (depends on 50)

The method or the polypeptide of claim 50, wherein total IL-6 levels in serum are maintained at at least 50 pg/ml for at least 8 weeks after administration.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method or the polypeptide of any of claims 1 to 51, wherein total IL-6 levels in serum are increased to and maintained at least 60 pg/ml for at least 4 weeks after administration.

### Claim 53 (depends on 52)

The method or the polypeptide of claim 52, wherein total IL-6 levels in serum are maintained at at least 60 pg/ml for at least 5 weeks after administration.

### Claim 54 (depends on 53)

The method or the polypeptide of claim 53, wherein total IL-6 levels in serum are maintained at at least 60 pg/ml for at least 6 weeks after administration.

### Claim 55 (depends on 54)

The method or the polypeptide of claim 54, wherein total IL-6 levels in serum are maintained at at least 60 pg/ml for at least 7 weeks after administration.

### Claim 56 (depends on 55)

The method or the polypeptide of claim 55, wherein total IL-6 levels in serum are maintained at at least 60 pg/ml for at least 8 weeks after administration.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method or the polypeptide of any of claims 1 to 56, wherein CRP levels in serum are reduced below 10 mg/l within two weeks after administration.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method or the polypeptide of any of claims 1 to 57, wherein CRP levels in serum are maintained below 10 mg/l for at least 4 weeks after administration.

### Claim 59 (depends on 58)

The method or the polypeptide of claim 58, wherein CRP levels in serum are maintained below 10 mg/l for at least 5 weeks after administration.

### Claim 60 (depends on 59)

The method or the polypeptide of claim 59, wherein CRP levels in serum are maintained below 10 mg/l for at least 6 weeks after administration.

### Claim 61 (depends on 60)

The method or the polypeptide of claim 60, wherein CRP levels in serum are maintained below 10 mg/l for at least 7 weeks after administration.

### Claim 62 (depends on 61)

The method or the polypeptide of claim 61, wherein CRP levels in serum are maintained below 10 mg/l for at least 8 weeks after administration.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method or the polypeptide of any of claims 1 to 62, wherein CRP levels in serum are decreased below and maintained below 9 mg/l for at least 4 weeks after administration.

### Claim 64 (depends on 63)

The method or the polypeptide of claim 63, wherein CRP levels in serum are maintained below 9 mg/l for at least 5 weeks after administration.

### Claim 65 (depends on 64)

The method or the polypeptide of claim 64, wherein CRP levels in serum are maintained below 9 mg/l for at least 6 weeks after administration.

### Claim 66 (depends on 65)

The method or the polypeptide of claim 65, wherein CRP levels in serum are maintained below 9 mg/l for at least 7 weeks after administration.

### Claim 67 (depends on 66)

The method or the polypeptide of claim 66, wherein CRP levels in serum are maintained below 9 mg/l for at least 8 weeks after administration.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method or the polypeptide of any of claims 1 to 67, wherein CRP levels in serum are decreased below and maintained below 8 mg/l for at least 4 weeks after administration.

### Claim 69 (depends on 68)

The method or the polypeptide of claim 68, wherein CRP levels in serum are maintained below 8 mg/l for at least 5 weeks after administration.

### Claim 70 (depends on 69)

The method or the polypeptide of claim 69, wherein CRP levels in serum are maintained below 8 mg/l for at least 6 weeks after administration.

### Claim 71 (depends on 70)

The method or the polypeptide of claim 70, wherein CRP levels in serum are maintained below 8 mg/l for at least 7 weeks after administration.

### Claim 72 (depends on 71)

The method or the polypeptide of claim 71, wherein CRP levels in serum are maintained below 8 g/l for at least 8 weeks after administration.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method or the polypeptide of any of claims 1 to 72, wherein CRP levels in serum are decreased below and maintained below 7.5 mg/l for at least 4 weeks after administration.

### Claim 74 (depends on 73)

The method or the polypeptide of claim 73, wherein CRP levels in serum are maintained below 7.5 mg/l for at least 5 weeks after administration.

### Claim 75 (depends on 74)

The method for the polypeptide of claim 74, wherein CRP levels in serum are maintained below 7.5 mg/l for at least 6 weeks after administration.

### Claim 76 (depends on 75)

The method or the polypeptide of claim 75, wherein CRP levels in serum are maintained below 7.5 mg/l for at least 7 weeks after administration.

### Claim 77 (depends on 76)

The method or the polypeptide of claim 76, wherein CRP levels in serum are maintained below 7.5 mg/l for at least 8 weeks after administration.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method or the polypeptide of any of claims 1 to 77, wherein CRP levels in serum are decreased below and maintained below 7 mg/l for at least 4 weeks after administration.

### Claim 79 (depends on 78)

The method or the polypeptide of claim 78, wherein CRP levels in serum are maintained below 7 mg/l for at least 5 weeks after administration.

### Claim 80 (depends on 79)

The method or the polypeptide of claim 79, wherein CRP levels in serum are maintained below 7 mg/l for at least 6 weeks after administration.

### Claim 81 (depends on 80)

The method or the polypeptide of claim 80, wherein CRP levels in serum are maintained below 7 mg/l for at least 7 weeks after administration.

### Claim 82 (depends on 81)

The method or the polypeptide of claim 81, wherein CRP levels in serum are maintained below 7 mg/l for at least 8 weeks after administration.

### Claim 83 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method or the polypeptide of any of claims 1 to 82, wherein CRP levels in serum are decreased below and maintained below 6.5 mg/l for at least 4 weeks after administration.

### Claim 84 (depends on 83)

The method or the polypeptide of claim 83, wherein CRP levels in serum are maintained below 6.5 mg/l for at least 5 weeks after administration.

### Claim 85 (depends on 84)

The method or the polypeptide of claim 84, wherein CRP levels in serum are maintained below 6.5 mg/l for at least 6 weeks after administration.

### Claim 86 (depends on 85)

The method or the polypeptide of claim 85, wherein CRP levels in serum are maintained below 6.5 mg/l for at least 7 weeks after administration.

### Claim 87 (depends on 86)

The method or the polypeptide of claim 86, wherein CRP levels in serum are maintained below 6.5 mg/l for at least 8 weeks after administration.

### Claim 88 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method or the polypeptide of any of claims 1 to 87, wherein CRP levels in serum are decreased below and maintained below 6 mg/l for at least 4 weeks after administration.

### Claim 89 (depends on 88)

The method or the polypeptide of claim 88, wherein CRP levels in serum are maintained below 6 mg/l for at least 5 weeks after administration.

### Claim 90 (depends on 89)

The method or the polypeptide of claim 89, wherein CRP levels in serum are maintained below 6 mg/l for at least 6 weeks after administration.

### Claim 91 (depends on 90)

The method or the polypeptide of claim 90, wherein CRP levels in serum are maintained below 6 mg/l for at least 7 weeks after administration.

### Claim 92 (depends on 91)

The method or the polypeptide of claim 91, wherein CRP levels in serum are maintained below 6 mg/l for at least 8 weeks after administration.

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method or the polypeptide of any of claims 1 to 92, wherein CRP levels in serum are decreased below and maintained below 5.5 mg/l for at least 4 weeks after administration.

### Claim 94 (depends on 93)

The method or the polypeptide of claim 93, wherein CRP levels in serum are maintained below 5.5 mg/l for at least 5 weeks after administration.

### Claim 95 (depends on 94)

The method or the polypeptide of claim 94, wherein CRP levels in serum are maintained below 5.5 mg/l for at least 6 weeks after administration.

### Claim 96 (depends on 95)

The method or the polypeptide of claim 95, wherein CRP levels in serum are maintained below 5.5 mg/l for at least 7 weeks after administration.

### Claim 97 (depends on 96)

The method or the polypeptide of claim 96, wherein CRP levels in serum are maintained below 5.5 mg/l for at least 8 weeks after administration.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method or the polypeptide of any of claims 1 to 97, wherein CRP levels in serum are decreased below and maintained below 5 mg/l for at least 4 weeks after administration.

### Claim 99 (depends on 98)

The method or the polypeptide of claim 98, wherein CRP levels in serum are maintained below 5 mg/l for at least 5 weeks after administration.

### Claim 100 (depends on 99)

The method or the polypeptide of claim 99, wherein CRP levels in serum are maintained below 5 mg/l for at least 6 weeks after administration.

### Claim 101 (depends on 100)

The method or the polypeptide of claim 100, wherein CRP levels in serum are maintained below 5 mg/l for at least 7 weeks after administration.

### Claim 102 (depends on 101)

The method or the polypeptide of claim 101, wherein CRP levels in serum are maintained below mg/l for at least 8 weeks after administration.

### Claim 103 (depends on 1, 102)

The method or the polypeptide of any of claims 1 to 102, wherein CRP levels in serum are reduced by 50% or more compared to baseline (i.e. pre-treatment or normal) levels within two weeks after administration.

### Claim 104 (depends on 1, 103)

The method or the polypeptide of any of claims 1 to 103, wherein CRP levels in serum are decreased by and maintained at 50% or more reduction compared to baseline levels for at least 4 weeks after administration.

### Claim 105 (depends on 104)

The method or the polypeptide of claim 104, wherein CRP levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 106 (depends on 105)

The method or the polypeptide of claim 105, wherein CRP levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 107 (depends on 106)

The method or the polypeptide of claim 106, wherein CRP levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 108 (depends on 107)

The method or the polypeptide of claim 107, wherein CRP levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 109 (depends on 1, 108)

The method or the polypeptide of any of claims 1 to 108, wherein CRP levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 110 (depends on 109)

The method or the polypeptide of claim 109, wherein CRP levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 111 (depends on 110)

The method or the polypeptide of claim 110, wherein CRP levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 112 (depends on 111)

The method or the polypeptide of claim 111, wherein CRP levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 113 (depends on 112)

The method or the polypeptide of claim 112, wherein CRP levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 114 (depends on 1, 113)

The method or the polypeptide of any of claims 1 to 113, wherein CRP levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 115 (depends on 114)

The method or the polypeptide of claim 114, wherein CRP levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 116 (depends on 115)

The method or the polypeptide of claim 115, wherein CRP levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 117 (depends on 116)

The method or the polypeptide of claim 116, wherein CRP levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 118 (depends on 117)

The method or the polypeptide of claim 117, wherein CRP levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 119 (depends on 1, 118)

The method or the polypeptide of any of claims 1 to 118, wherein ESR levels in serum are reduced by 30% or more compared to baseline (i.e. pre-treatment or normal) levels within two weeks after administration.

### Claim 120 (depends on 1, 119)

The method or the polypeptide of any of claims 1 to 119, wherein ESR levels in serum are decreased by and maintained at 30% or more reduction compared to baseline levels for at least 4 weeks after administration.

### Claim 121 (depends on 120)

The method or the polypeptide of claim 120, wherein ESR levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 122 (depends on 121)

The method or the polypeptide of claim 121, wherein ESR levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 6 weeks after administration,

### Claim 123 (depends on 122)

The method or the polypeptide of claim 122, wherein ER levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 124 (depends on 123)

The method or the polypeptide of claim 123, wherein ESR levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 125 (depends on 1, 124)

The method or the polypeptide of any of claims 1 to 124, wherein ESR levels in serum are decreased by and maintained at 40% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 126 (depends on 125)

The method or the polypeptide of claim 125, wherein ESR levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 127 (depends on 126)

The method or the polypeptide of claim 126, wherein ESR levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 128 (depends on 127)

The method or the polypeptide of claim 127, wherein ESR levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 129 (depends on 128)

The method or the polypeptide of claim 128, wherein ESR levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 130 (depends on 1, 129)

The method or the polypeptide of any of claims 1 to 129, wherein ESR levels in serum are decreased by and maintained at 50% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 131 (depends on 130)

The method or the polypeptide of claim 130, wherein ESR levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 132 (depends on 131)

The method or the polypeptide of claim 131, wherein ESR levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 133 (depends on 132)

The method or the polypeptide of claim 132, wherein ESR levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 134 (depends on 133)

The method or the polypeptide of claim 133, wherein ESR levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 135 (depends on 1, 134)

The method or the polypeptide of any of claims 1 to 134, wherein ESR levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 136 (depends on 135)

The method or the polypeptide of claim 135, wherein ESR levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 137 (depends on 136)

The method or the polypeptide of claim 136, wherein ESR levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 138 (depends on 137)

The method or the polypeptide of claim 137, wherein ESR levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 139 (depends on 138)

The method or the polypeptide of claim 138, wherein ESR levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 140 (depends on 1, 139)

The method or the polypeptide of any of claims 1 to 139, wherein ESR levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 141 (depends on 140)

The method or the polypeptide of claim 140, wherein ESR levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 142 (depends on 141)

The method or the polypeptide of claim 141, wherein ESR levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 143 (depends on 142)

The method or the polypeptide of claim 142, wherein BR levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 144 (depends on 143)

The method or the polypeptide of claim 143, wherein ESR levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 145 (depends on 1, 144)

The method or the polypeptide of any of claims 1 to 144, wherein fibrinogen levels in serum are reduced by 30% or more compared to baseline (i.e. pre-treatment or normal) levels within two weeks after administration.

### Claim 146 (depends on 1, 145)

The method or the polypeptide of any of claims 1 to 145, wherein fibrinogen levels in serum are decreased by and maintained at 30% or more reduction compared to baseline levels for at least 4 weeks after administration.

### Claim 147 (depends on 146)

The method or the polypeptide of claim 146, wherein fibrinogen levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 148 (depends on 147)

The method or the polypeptide of claim 147, wherein fibrinogen levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 149 (depends on 148)

The method or the polypeptide of claim 148, wherein fibrinogen levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 150 (depends on 149)

The method or the polypeptide of claim 149, wherein fibrinogen levels in serum are maintained at 30% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 151 (depends on 1, 150)

The method or the polypeptide of any of claims 1 to 150, wherein fibrinogen levels in serum are decreased by and maintained at 40% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 152 (depends on 151)

The method or the polypeptide of claim 151, wherein fibrinogen levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 153 (depends on 152)

The method or the polypeptide of claim 152, wherein fibrinogen levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 154 (depends on 153)

The method or the polypeptide of claim 153, wherein fibrinogen levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 155 (depends on 154)

The method or the polypeptide of claim 154, wherein fibrinogen levels in serum are maintained at 40% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 156 (depends on 1, 155)

The method or the polypeptide of any of claims 1 to 155, wherein fibrinogen levels in serum are decreased by and maintained at 50% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 157 (depends on 156)

The method or the polypeptide of claim 156, wherein fibrinogen levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 158 (depends on 157)

The method or the polypeptide of claim 157, wherein fibrinogen levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 159 (depends on 158)

The method or the polypeptide of claim 158, wherein fibrinogen levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 160 (depends on 159)

The method or the polypeptide of claim 159, wherein fibrinogen levels in serum are maintained at 50% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 161 (depends on 1, 160)

The method or the polypeptide of any of claims 1 to 160, wherein fibrinogen levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 162 (depends on 161)

The method or the polypeptide of claim 161, wherein fibrinogen levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 163 (depends on 162)

The method or the polypeptide of claim 162, wherein fibrinogen levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 164 (depends on 163)

The method or the polypeptide of claim 163, wherein fibrinogen levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 165 (depends on 164)

The method or the polypeptide of claim 164, wherein fibrinogen levels in serum are maintained at 60% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 166 (depends on 1, 165)

The method or the polypeptide of any of claims 1 to 165, wherein fibrinogen levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 167 (depends on 166)

The method or the polypeptide of claim 166, wherein fibrinogen levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 168 (depends on 167)

The method or the polypeptide of claim 167, wherein fibrinogen levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 169 (depends on 168)

The method or the polypeptide of claim 168, wherein fibrinogen levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 170 (depends on 169)

The method or the polypeptide of claim 169, wherein fibrinogen levels in serum are maintained at 70% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 171 (depends on 1, 170)

The method or the polypeptide of any of claims 1 to 170, wherein serum amyloid A levels are reduced by 30% or more compared to baseline (i.e. pre-treatment or normal) levels within two weeks after administration.

### Claim 172 (depends on 1, 171)

The method or the polypeptide of any of claims 1 to 171, wherein serum amyloid A levels are decreased by and maintained at 30% or more reduction compared to baseline levels for at least 4 weeks after administration.

### Claim 173 (depends on 172)

The method or the polypeptide of claim 172, wherein serum amyloid A levels are maintained at 30% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 174 (depends on 173)

The method or the polypeptide of claim 173, wherein serum amyloid A levels are maintained at 30% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 175 (depends on 174)

The method or the polypeptide of claim 174, wherein serum amyloid A levels are maintained at 30% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 176 (depends on 175)

The method or the polypeptide of claim 175, wherein serum amyloid A levels are maintained at 30% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 177 (depends on 1, 176)

The method or the polypeptide of any of claims 1 to 176, wherein serum amyloid A levels are decreased by and maintained at 40% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 178 (depends on 177)

The method or the polypeptide of claim 177, wherein serum amyloid A levels are maintained at 40% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 179 (depends on 178)

The method or the polypeptide of claim 178, wherein serum amyloid A levels are maintained at 40% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 180 (depends on 179)

The method or the polypeptide of claim 179, wherein serum amyloid A levels are maintained at 40% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 181 (depends on 180)

The method or the polypeptide of claim 180, wherein serum amyloid A levels are maintained at 40% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 182 (depends on 1, 181)

The method or the polypeptide of any of claims 1 to 181, wherein serum amyloid A levels are decreased by and maintained at 50% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 183 (depends on 182)

The method or the polypeptide of claim 182, wherein serum amyloid A levels are maintained at 50% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 184 (depends on 183)

The method or the polypeptide of claim 183, wherein serum amyloid A levels are maintained at 50% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 185 (depends on 184)

The method or the polypeptide of claim 184, wherein serum amyloid A levels are maintained at 50% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 186 (depends on 185)

The method or the polypeptide of claim 185, wherein serum amyloid A levels are maintained at 50% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 187 (depends on 1, 186)

The method or the polypeptide of any of claims 1 to 186, wherein serum amyloid A levels are decreased by and maintained at 60% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 188 (depends on 187)

The method or the polypeptide of claim 187, wherein serum amyloid A levels are maintained at 60% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 189 (depends on 188)

The method or the polypeptide of claim 188, wherein serum amyloid A levels are maintained at 60% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 190 (depends on 189)

The method or the polypeptide of claim 189, wherein serum amyloid A levels are maintained at 60% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 191 (depends on 190)

The method or the polypeptide of claim 190, wherein serum amyloid A levels are maintained at 60% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 192 (depends on 1, 191)

The method or the polypeptide of any of claims 1 to 191, wherein serum amyloid A levels are decreased by and maintained at 70% or more (reduction) compared to baseline levels for at least 4 weeks after administration.

### Claim 193 (depends on 192)

The method or the polypeptide of claim 192, wherein serum amyloid A levels are maintained at 70% or more reduction compared to baseline levels for at least 5 weeks after administration.

### Claim 194 (depends on 193)

The method or the polypeptide of claim 193, wherein serum amyloid A levels are maintained at 70% or more reduction compared to baseline levels for at least 6 weeks after administration.

### Claim 195 (depends on 194)

The method or the polypeptide of claim 194, wherein serum amyloid A levels are maintained at 70% or more reduction compared to baseline levels for at least 7 weeks after administration.

### Claim 196 (depends on 195)

The method or the polypeptide of claim 195, wherein serum amyloid A levels are maintained at 70% or more reduction compared to baseline levels for at least 8 weeks after administration.

### Claim 197 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method or the polypeptide of any of claims 1 to 23, wherein the polypeptide is administered as a multiple dose.

### Claim 198 (depends on 197)

The method or the polypeptide of claim 197, wherein the polypeptide is administered every 4 to 8 weeks.

### Claim 199 (depends on 198)

The method or the polypeptide of claim 198, wherein the polypeptide is administered every 4 weeks.

### Claim 200 (depends on 199)

The method or the polypeptide of claim 199, wherein the polypeptide is administered at about 3 mg/kg every 4 weeks.

### Claim 201 (depends on 199)

The method or the polypeptide of claim 199, wherein the polypeptide is administered at about 6 mg/kg every 4 weeks.

### Claim 202 (depends on 198)

The method or the polypeptide of claim 198, wherein the polypeptide is administered every 8 weeks.

### Claim 203 (depends on 202)

The method or the polypeptide of claim 202, wherein the polypeptide is administered at about 6 mg/kg every 8 weeks.

### Claim 204 (depends on 197, 198, 199, 200, 201, 202, 203)

The method or polypeptide of any of claims 197 to 203, wherein total sIL-6R levels in serum are increased to and maintained at least 400 ng/ml (throughout the treatment period).

### Claim 205 (depends on 204)

The method or the polypeptide of claim 204, wherein total sIL-6R levels in serum are increased to and maintained at least 500 ng/ml (throughout the treatment period).

### Claim 206 (depends on 205)

The method or the polypeptide of claim 205, wherein total sIL-6R levels in serum are increased to and maintained at least 600 ng/ml (throughout the treatment period).

### Claim 207 (depends on 206)

The method or the polypeptide of claim 206, wherein total sIL-6R levels in serum are increased to and maintained at least 650 ng/ml (throughout the treatment period).

### Claim 208 (depends on 207)

The method or the polypeptide of claim 207, wherein total sIL-6R levels in serum are increased to and maintained at least 700 ng/ml (throughout the treatment period).

### Claim 209 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208)

The method or the polypeptide of any of claims 197 to 208, wherein total IL-6 levels in serum are increased to and maintained at least 40 pg/ml (throughout the treatment period).

### Claim 210 (depends on 209)

The method or the polypeptide of claim 209, wherein total IL-6 levels in serum are increased to and maintained at least 50 pg/ml (throughout the treatment period).

### Claim 211 (depends on 210)

The method or the polypeptide of claim 210, wherein total IL-6 levels in serum are increased to and maintained at least 60 pg/ml (throughout the treatment period).

### Claim 212 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211)

The method or the polypeptide of any of claims 197 to 211, wherein CRP levels in serum are decreased below and maintained below 10 mg/l (throughout the treatment period).

### Claim 213 (depends on 212)

The method or the polypeptide of claim 212, wherein CRP levels in serum are decreased below and maintained below 9 mg/l (throughout the treatment period).

### Claim 214 (depends on 213)

The method or the polypeptide of claim 213, wherein CRP levels in serum are decreased below and maintained below 8 mg/l (throughout the treatment period).

### Claim 215 (depends on 214)

The method or the polypeptide of claim 214, wherein CRP levels in serum are decreased below and maintained below 7.5 mg/l (throughout the treatment period).

### Claim 216 (depends on 215)

The method or the polypeptide of claim 215, wherein CRP levels in serum are decreased below and maintained below 7 mg/l (throughout the treatment period).

### Claim 217 (depends on 216)

The method or the polypeptide of claim 216, wherein CRP levels in serum are decreased below and maintained below 6.5 mg/l (throughout the treatment period).

### Claim 218 (depends on 217)

The method or the polypeptide of claim 217, wherein CRP levels in serum are decreased below and maintained below 6 mg/l (throughout the treatment period).

### Claim 219 (depends on 218)

The method or the polypeptide of claim 218, wherein CRP levels in serum are decreased below and maintained below 5.5 mg/l (throughout the treatment period).

### Claim 220 (depends on 219)

The method or the polypeptide of claim 219, wherein CRP levels in serum are decreased below and maintained below 5 mg/l (throughout the treatment period).

### Claim 221 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220)

The method or the polypeptide of any of claims 197 to 220, wherein CRP levels in serum are decreased by and maintained at 50% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 222 (depends on 221)

The method or the polypeptide of claim 221, wherein CRP levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 223 (depends on 222)

The method or the polypeptide of claims 222, wherein CRP levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline (throughout the treatment period).

### Claim 224 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223)

The method or the polypeptide of any of claims 197 to 223, wherein ESR levels in serum are decreased by and maintained at 30% or more (reduction) compared to baseline levels.

### Claim 225 (depends on 224)

The method or the polypeptide of claim 224, wherein ESR levels in serum are decreased by and maintained at 40% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 226 (depends on 225)

The method or the polypeptide of claim 225, wherein ESR levels in serum are decreased by and maintained at 50% or more (reduction) compared to baseline (throughout the treatment period).

### Claim 227 (depends on 226)

The method or the polypeptide of claim 226, wherein ESR levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 228 (depends on 227)

The method or the polypeptide of claim 227, wherein ESR levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 229 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228)

The method or the polypeptide of any of claims 197 to 228, wherein fibrinogen levels in serum are decreased by and maintained at 30% or more reduction compared to baseline levels (throughout the treatment period).

### Claim 230 (depends on 229)

The method or the polypeptide of claim 229, wherein fibrinogen levels in serum are decreased by and maintained at 40% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 231 (depends on 230)

The method or the polypeptide of claim 230, wherein fibrinogen levels in serum are decreased by and maintained at 50% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 232 (depends on 231)

The method or the polypeptide of claim 231, wherein fibrinogen levels in serum are decreased by and maintained at 60% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 233 (depends on 232)

The method or the polypeptide of claim 232, wherein fibrinogen levels in serum are decreased by and maintained at 70% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 234 (depends on 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233)

The method or the polypeptide of any of claims 197 to 233, wherein serum amyloid A levels are decreased by and maintained at 30% or more reduction compared to baseline levels (throughout the treatment period).

### Claim 235 (depends on 234)

The method or the polypeptide of claim 234, wherein serum amyloid A levels are decreased by and maintained at 40% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 236 (depends on 235)

The method or the polypeptide of claim 235, wherein serum amyloid A levels are decreased by and maintained at 50% or more (reduction) compared to baseline (throughout the treatment period).

### Claim 237 (depends on 236)

The method or the polypeptide of claim 236, wherein serum amyloid A levels are decreased by and maintained at 60% or more (reduction) compared to baseline levels (throughout the treatment period).

### Claim 238 (depends on 237)

The method or the polypeptide of claim 237, wherein serum amyloid A levels are decreased by and maintained at 70% or more (reduction) compared to baseline levels (throughout the treatment period).
